Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Real-World Evidence of Incidence and Outcomes of Aplastic Anemia Following Administration of Immune Checkpoint Inhibitors

Srilatha Dasari, William Tse, Jiasheng Wang

Blood (2022) 140 (Supplement 1): 712–713.

https://doi.org/10.1182/blood-2022-168353

Published: 2022

Journal Articles

Response Kinetics of Daratumumab-Based Regimens in Patients with Newly Diagnosed or Refractory/Relapsed Multiple Myeloma

Jiasheng Wang, Raul Arroyo-Suarez, William Tse

Blood (2021) 138 (Supplement 1): 3806.

https://doi.org/10.1182/blood-2021-149315

Published: 2021

Journal Articles

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

Farhad Ravandi, MBBS, Christopher Pocock, MBBS, Dominik Selleslag, MD, Pau Montesinos, MD PhD, Hamid Sayar, MD MSc, Maurizio Musso, MD, Angela Figuera Alvarez, Hana Safah, MD, William Tse, MD FACP, Sang Kyun Sohn, MDPhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Timothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Hervé Dombret, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-137669

Published: 2020

Journal Articles

Risk of Non-Hodgkin's Lymphoma in HCV Patients in the United States between 2013 and 2020: A Population-Based Study

Akram Alkrekshi, MD, Ahmad Kassem, MD, Changsu Park, MD, William Tse, MD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-142472

Published: 2020

Journal Articles

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Adetola A. Kassim, MDMS, Josu de la Fuente, Ali Debsan Alahmari, MBBS, MD MNAMS, Michael J. Eckrich, MD MPH, Rabi Hanna, MD, Nathalie Dhedin, MD, Biljana N. Horn, MD, Vandy Black, MDMSc, Roseane V Gouveia, Adriana Seber, MDMS, Belinda Pinto Simões, MD PhD, Thalita Cristina de Mello Costa, MD, Renato Guerino-Cunha, Carmem M. S. Bonfim, MDPhD, Roberto Luiz da Silva, Nelson Hamerschlak, MD PhD, Juliana Folloni Fernandes, MD, Michael Kent, MDBS, Satya Prakash Yadav, MBBS, MD, Erfan Nur, MDPhD, Mohsen Alzahrani, Ben Carpenter, PhD, William Tse, MD, Maria Isabel, Hemalatha G Rangarajan, MD, Ibrahim Ahmed, MD, Adeseye Michael Akinsete, MBBS, Courtney D. Fitzhugh, MD, Kathryn A. Culos, PharmD, Leena Karnik, FRCPath, MRCP, James Connelly, MD, Carrie Kitko, MD, Jennifer Andrews, MDMSc, Karina L Wilkerson, NP, MSN, Robert Brodsky, Tatsuki Koyama, Michael R. DeBaun, MD MPH

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-141771

Published: 2020

Journal Articles

Epidemiology of Visceral Mycoses in Patients with Acute Leukemia and Myelodysplastic Syndrome: Analyzing the National Autopsy Database in Japan

Tomiteru Togano, MD PhD, Yuhko Suzuki, MD PhD, William Tse, MD, Hikaru Kume, PharmD, PhD

Blood (2018) 132 (Supplement 1): 3602.

https://doi.org/10.1182/blood-2018-99-110546

Published: 2018

Journal Articles

Evaluating and Correcting Iron Deficit in Atypical Hemolytic Uremic Syndrome (HUS)

Samuel B Reynolds, MD BS, William Tse, MD

Blood (2018) 132 (Supplement 1): 5002.

https://doi.org/10.1182/blood-2018-99-112353

Published: 2018

Journal Articles

Clinical Outcomes Using Mycophenolate and Tacrolimus for Graft Versus Host Disease Prophylaxis in Patients Undergoing Allogenic Stem Cell Transplant: A Single Institution Experience

Hamza Hashmi, MD, Shruti Bhandari, MD, Xiaoyong Wu, Shesh Nath Rai, William Tse, MD, Robert V.B. Emmons, MD

Blood (2018) 132 (Supplement 1): 5728.

https://doi.org/10.1182/blood-2018-99-115422

Published: 2018

Journal Articles

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose

Ehab L. Atallah, MD, Johnnie J. Orozco, MD PhD, Michael Craig, MD, Moshe Yair Levy, MD, Laura E. Finn, MD, Sharif S. Khan, MD, Alexander E. Perl, MD, Jae H. Park, MD, Gail J. Roboz, MD, William Tse, MD, Kebede H. Begna, MD, Raya Mawad, MD, David A. Rizzieri, MD, Mark S. Berger, MD, Joseph G. Jurcic, MD

Blood (2018) 132 (Supplement 1): 1457.

https://doi.org/10.1182/blood-2018-99-111951

Published: 2018

Journal Articles

VRD-CEP: An Effective and Tolerable Chemo-Mobilization and Debulking Regimen for Multiple Myeloma

Hamza Hashmi, MD, Suresh Manapuram, MD, Timothy C. Baize, PharmD, Lindsay Figg, PharmD, Soumit K. Basu, MD PhD, William Tse, MD, Maxwell M. Krem, MD PhD

Blood (2017) 130 (Supplement 1): 3203.

https://doi.org/10.1182/blood.V130.Suppl_1.3203.3203

Published: 2017

Journal Articles

Weekly Dosing of Bortezomib in RVD Achieves Minimal Toxicity with No Reduction in Efficacy in a Diverse Cohort of Multiple Myeloma Patients

Syed Hussaini, MD, Amitoj Gill, MD, Rahul Gosain, MD, Shesh Rai, PhD, Xiaoyong Wu, Jill Rhodes, Pharm D, Soumit K. Basu, MD PhD, Ju-Hsien Chao, DO, William Tse, MD, Geoffrey P. Herzig, MD, Roger H. Herzig, MD, Maxwell M. Krem, MD PhD

Blood (2017) 130 (Supplement 1): 5425.

https://doi.org/10.1182/blood.V130.Suppl_1.5425.5425

Published: 2017

Journal Articles

A Phase II Study of Midostaurin and 5-Azacitidine for Elderly Patients with Acute Myeloid Leukemia

Molly M Gallogly, MDPhD, Ben K. Tomlinson, MD, Pam Bunner, MT, CCRC, Paolo Caimi, MD, Michael Craig, MD, Marcos de Lima, MD, Stanton L. Gerson, MD, Donna Kane, RN, MSN, Hillard M Lazarus, MD, Mark J. Levis, MD, Ehsan Malek, MD, Jane A. Little, MD, Crystal Street, MT, CCRC, Willem J. van Heeckeren, MD PhD, William Tse, MD, Brenda W. Cooper, MD

Blood (2017) 130 (Supplement 1): 1332.

https://doi.org/10.1182/blood.V130.Suppl_1.1332.1332

Published: 2017

Journal Articles

Use of a Hemoglobin Substitute (HBOC-201) to Treat Acute Anemia in a Leukemic Patient with Anti-Vel Antibodies

M. Tayyeb Ayyoubi, MD, Suresh Manapuram, MD, Hamza Hashmi, MD, Katherine McDaniel, MLS (ASCP), Soumit K. Basu, MD PhD, William Tse, MD, Maxwell M. Krem, MD PhD

Blood (2017) 130 (Supplement 1): 4928.

https://doi.org/10.1182/blood.V130.Suppl_1.4928.4928

Published: 2017

Journal Articles

Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML)

Blood (2015) 126 (23): 2536.

https://doi.org/10.1182/blood.V126.23.2536.2536

Published: 2015

Journal Articles

High Expression of AF1q Is an Adverse Prognostic Factor in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation

Shotaro Hagiwara, Ana-Iris Schiefer, MD, Sohtaro MINE, MD BPharm, BA, Lukas Kenner, MD, PhD, William Tse, MD FACP

Blood (2015) 126 (23): 5321.

https://doi.org/10.1182/blood.V126.23.5321.5321

Published: 2015

Journal Articles

HIF-1a Pathway, As a Signal Funnel for Genetic, Epigenetic, and Metabolic Aberrations, Is Sufficient and Essential for MDS Development

Blood (2015) 126 (23): 303.

https://doi.org/10.1182/blood.V126.23.303.303

Published: 2015

Journal Articles

Synergistic Cytotoxicity in Acute Myeloid Leukemia By Combined Treatment with Metformin and 6-Benzylthioinosine

Himalee S. Sabnis, Shweta Tripathi, Heath L Bradley, Wen-Mei Yu, William Tse, Cheng-Kui Qu, Kevin D. Bunting

Blood (2014) 124 (21): 3754.

https://doi.org/10.1182/blood.V124.21.3754.3754

Published: 2014

Journal Articles

RUNX1/CBFβ Dosage Is Critical for MLL Leukemias Development

Blood (2014) 124 (21): 2187.

https://doi.org/10.1182/blood.V124.21.2187.2187

Published: 2014

Journal Articles

Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal

Blood (2014) 123 (11): 1729–1738.

https://doi.org/10.1182/blood-2013-03-489575

Published: 2014

Includes: Supplemental data

Journal Articles

STAT5 Promotes Hematopoietic Stem Cell Maintenance by Increasing Quiescence-Associated Gene Expression and Suppressing Lymphoid Commitment

Zhengqi Wang, PhD, Geqiang Li, PhD, Zizhen Kang, MD, Tamisha Y. Vaughan, PhD, Silvia T Bunting, MD, William Tse, MD, Kevin D. Bunting, PhD

Blood (2012) 120 (21): 851.

https://doi.org/10.1182/blood.V120.21.851.851

Published: 2012

NARROW

Real-World Evidence of Incidence and Outcomes of Aplastic Anemia Following Administration of Immune Checkpoint Inhibitors

Response Kinetics of Daratumumab-Based Regimens in Patients with Newly Diagnosed or Refractory/Relapsed Multiple Myeloma

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

Risk of Non-Hodgkin's Lymphoma in HCV Patients in the United States between 2013 and 2020: A Population-Based Study

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Epidemiology of Visceral Mycoses in Patients with Acute Leukemia and Myelodysplastic Syndrome: Analyzing the National Autopsy Database in Japan

Evaluating and Correcting Iron Deficit in Atypical Hemolytic Uremic Syndrome (HUS)

Clinical Outcomes Using Mycophenolate and Tacrolimus for Graft Versus Host Disease Prophylaxis in Patients Undergoing Allogenic Stem Cell Transplant: A Single Institution Experience

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose

VRD-CEP: An Effective and Tolerable Chemo-Mobilization and Debulking Regimen for Multiple Myeloma

Weekly Dosing of Bortezomib in RVD Achieves Minimal Toxicity with No Reduction in Efficacy in a Diverse Cohort of Multiple Myeloma Patients

A Phase II Study of Midostaurin and 5-Azacitidine for Elderly Patients with Acute Myeloid Leukemia

Use of a Hemoglobin Substitute (HBOC-201) to Treat Acute Anemia in a Leukemic Patient with Anti-Vel Antibodies

Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML)

High Expression of AF1q Is an Adverse Prognostic Factor in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation

HIF-1a Pathway, As a Signal Funnel for Genetic, Epigenetic, and Metabolic Aberrations, Is Sufficient and Essential for MDS Development

Synergistic Cytotoxicity in Acute Myeloid Leukemia By Combined Treatment with Metformin and 6-Benzylthioinosine

RUNX1/CBFβ Dosage Is Critical for MLL Leukemias Development

Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal

STAT5 Promotes Hematopoietic Stem Cell Maintenance by Increasing Quiescence-Associated Gene Expression and Suppressing Lymphoid Commitment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only